Previous study reported that SNRPB promotes the tumor formation of NSCLC by regulating RAB26 and SNRPB may predict response to cisplatin-based chemotherapy for NSCLC patients (Liu et al., 2019; Liu et al., 2021). Here, RAB26 is linked to non-small cell lung carcinoma.